Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Sep 25;29(10):2643–2655. doi: 10.1038/s41591-023-02553-8

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023, corrected publication 2024

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — a, RT-qPCR analysis of PNPLA3 mRNA level in the human HepG2 cell line treated for 48 h with E₂ (1 μM), PPT (1 μM), DPN (1 μM), tamoxifen (10 μM), G-1 (1 μM) and dimethyl sulfoxide (DMSO) as a negative control. b,c, Western blot analysis of PNPLA3 protein levels in HepG2 cells treated with E₂ or tamoxifen and DMSO as a negative control (glyceraldehyde 3-phosphate dehydrogenase (GAPDH) used as loading control run on a different gel) (b) and relative quantification (c). d, Western blot analysis of PNPLA3, PLIN2 and GAPDH proteins in cytosolic and lipid droplet fractions obtained from cells treated for 48 h with fatty acids (oleic and palmitic acids, both at 250 μM) and tamoxifen or DMSO as a negative control. e, RT-qPCR analysis of PNPLA3 mRNA level in HLOs treated for 48 h with tamoxifen (10 μM) and DMSO as a negative control. f, Relative quantification of ORO staining for visualization of intracellular neutral lipids of HepG2 treated for 48 h with E₂ (1 μM), tamoxifen (10 μM) and DMSO as a negative control. g, Immunofluorescence staining of DAPI (blue) and COL1A1 (red) of 3D spheroids (HepG2:LX-2, 24:1) treated for 48 h with a mix of palmitic and oleic acids (PAOA, 250 μM each), TGF-β (10 ng ml⁻¹) and tamoxifen (10 μM) or DMSO as a negative control. Scale bar, 50 μm. h, Quantification of COL1A1 levels by ImageJ normalized to DAPI quantification. a.u., arbitrary units. Whiskers show minimum to maximum values, box bounds the 25th to 75th percentiles and the center the median value. Data in a, c and e are presented as mean ± s.e.m. (n = 3 independent experiments). One-way ANOVA followed by Bonferroni’s post hoc test were used. Data in f are represented as mean ± s.e.m. (n = 3 independent experiments). A two-sided, unpaired Student’s t-test was used. Data in h are mean ± s.e.m. (n = 9 from 3 independent experiments). A one-way ANOVA was followed by Bonferroni’s post hoc test.

Source data